Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kaken Set to Take Stab at US Market with Vascular Malformation Drug
Kaken Pharmaceutical aims to branch out into the US market now that it has successfully clinched a major out-licensing deal ahead of schedule, with its drug discovery work producing favorable results, President Hiroyuki Horiuchi says. “We’re now at a point…
To read the full story
Related Article
- Kaken Closes US$103 Million Acquisition of Aadi Subsidiary
March 28, 2025
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
- Kaken to Snatch Up Aadi Subsidiary for US$100 Million to Establish Global Footprint
December 23, 2024
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…